AMENDMENTS TO THE CLAIMS

1. (Original) A method of increasing the oral bioavailability of glycopyrrolate to a patient receiving glycopyrrolate therapy comprising administering to the patient a therapeutically effective amount of glycopyrrolate in a pharmaceutical composition without food.

2. (Original) The method of claim 1 wherein the therapeutically effective amount of glycopyrrolate is 1 mg to 10 mg.

3. (Original) The method of claim 2 wherein the therapeutically effective amount of glycopyrrolate is 1 mg to 2 mg.

4. (Original) The method of claim 1 wherein the patient has not consumed food during the period between from at least about 30 minutes prior to the administration of glycopyrrolate to at least about 1 hour after the administration of glycopyrrolate.

5. (Original) The method of claim 1 wherein the patient has not consumed food during the period between from at least about 1 hour prior to the administration of glycopyrrolate to at least about 2 hours after the administration of glycopyrrolate.

6. (Original) The method of claim 1 wherein the pharmaceutical composition comprises a unit dosage form for oral administration.

7. (Original) The method of claim 6 wherein the unit dosage form is a tablet.

8. (Currently Amended) A method of increasing the extent of absorption of an oral dosage form of glycopyrrolate as measured by the drug concentration attained in the blood stream over time in a patient in need of a therapeutic effect thereof comprising[[,]] administering to the patient a therapeutically effective amount of glycopyrrolate in a pharmaceutical composition without food.

9. (Original) The method of claim 8 wherein the therapeutically effective amount of glycopyrrolate is about 1 mg to about 10 mg.

10. (Original) The method of claim 9 wherein the therapeutically effective amount of glycopyrrolate is about 1 mg to about 2 mg.

11. (Original) The method of claim 8 wherein the patient has not consumed food during the period between from at least about 30 minutes prior to the administration of glycopyrrolate to at least about 1 hour after the administration of glycopyrrolate.

12. (Original) The method of claim 8 wherein the patient has not consumed food during the period between from at least about 1 hour prior to the administration of glycopyrrolate to at least about 2 hours after the administration of glycopyrrolate.

13. (Original) The method of claim 8 wherein the pharmaceutical composition comprises a unit dosage form for oral administration.

14. (Original) The method of claim 13 wherein the unit dosage form is a tablet.

15. (Original) A method of increasing the oral bioavailability of glycopyrrolate to a patient receiving glycopyrrolate therapy comprising administering to the patient a pharmaceutical tablet comprising about 1 mg to about 10 mg of glycopyrrolate under fasted conditions, wherein the administration results in an increase of the maximum plasma concentration (C_{max}) and the extent of absorption of glycopyrrolate at t = 24 hours ($AUC_{0\text{-}24hrs}$) as compared to the administration of glycopyrrolate under fed conditions.

16. (Original) The method of claim 15 wherein the ratio of C_{max} following administration without food to C_{max} following administration with food is greater than about 1.1, and wherein the ratio of $AUC_{0\text{-}24hrs}$ following administration without food to $AUC_{0\text{-}24hrs}$ following administration with food is greater than about 1.8.

17. (Original) The method of claim 16 wherein the ratio of C_{max} following administration without food to C_{max} following administration with food is greater than about 2.8, and wherein the ratio of $AUC_{0\text{-}24hrs}$ following administration without food to $AUC_{0\text{-}24hrs}$ following administration with food is greater than about 4.5.

18. (Original) The method of claim 16, further comprising informing the patient that the administration of the glycopyrrolate dose in a pharmaceutical composition under fasted conditions results in an increase of the maximum plasma concentration (C_{max})

and the extent of absorption of glycopyrrolate at t = 24 hours ($AUC_{0\text{-}24hrs}$) as compared to the administration of glycopyrrolate under fed conditions.

19. (Original) The method of claim 18, wherein the pharmaceutical composition is provided to a patient in a container associated with prescribing information that advises the patient that the administration of the glycopyrrolate dose in a pharmaceutical composition under fasted conditions results in an increase of the maximum plasma concentration (C_{max}) and the extent of absorption of glycopyrrolate at t = 24 hours ($AUC_{0\text{-}24hrs}$) as compared to the administration of glycopyrrolate under fed conditions.

20–27. (Canceled)

This listing of claims replaces all prior versions, and listings, of claims in the application.